Aducanumab and the FDA - where are we now?
- PMID: 33442064
- DOI: 10.1038/s41582-020-00454-9
Aducanumab and the FDA - where are we now?
References
-
- US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02477800 (2020).
-
- US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02484547 (2020).
-
- US National Library of Medicine. ClincialTrials.gov https://clinicaltrials.gov/ct2/show/NCT01677572 (2020).
-
- Biogen. Biogen and Eisai to Discontinue Phase 3 ENGAGE and EMERGE Trials of aducanumab in Alzheimer’s disease. Investors.biogen.com https://investors.biogen.com/news-releases/news-release-details/biogen-a... (2019).
-
- Food and Drug Administration. November 6, 2020 BLA 761178: Peripheral and Central Nervous System Drugs Advisory Committee Meeting. fda.gov https://www.fda.gov/media/143505/download (2020).
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
